|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for CAMK2B |
 Gene summary |
| Basic gene Info. | Gene symbol | CAMK2B |
| Gene name | calcium/calmodulin-dependent protein kinase II beta | |
| Synonyms | CAM2|CAMK2|CAMKB | |
| Cytomap | UCSC genome browser: 7p14.3-p14.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001220.4, NM_001293170.1,NM_172078.2,NM_172079.2,NM_172080.2, NM_172081.2,NM_172082.2,NM_172083.2,NM_172084.2, | |
| Description | CaM kinase II beta subunitCaM-kinase II beta chaincaMK-II subunit betacalcium/calmodulin-dependent protein kinase type II subunit betaproline rich calmodulin-dependent protein kinase | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 607707 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000058404 | ||
| HPRD : 12127 | ||
| Vega : OTTHUMG00000023491 | ||
| Protein | UniProt: Q13554 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CAMK2B | |
| BioGPS: 816 | ||
| Pathway | NCI Pathway Interaction Database: CAMK2B | |
| KEGG: CAMK2B | ||
| REACTOME: CAMK2B | ||
| Pathway Commons: CAMK2B | ||
| Context | iHOP: CAMK2B | |
| ligand binding site mutation search in PubMed: CAMK2B | ||
| UCL Cancer Institute: CAMK2B | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0046777 | protein autophosphorylation | 18817731 |
| Top |
| Ligand binding site mutations for CAMK2B |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | K43 | I44V | LUAD | 1 | V74 | R75C | LUAD | 1 | E140 | P139S | SKCM | 1 | V28 | R30S | STAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for CAMK2B |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | V28 | R30S | -1.2097334 | V74 | R75C | -1.1043533 | E140 | P139S | -0.81277242 | K43 | I44V | -0.77848083 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for CAMK2B from PDB |
| Top |
| Differential gene expression and gene-gene network for CAMK2B |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for CAMK2B |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0036341 | Schizophrenia | 3 | AlteredExpression, Biomarker |
| umls:C0236736 | Cocaine-Related Disorders | 1 | Biomarker |
| umls:C0024809 | Marijuana Abuse | 1 | Biomarker |
| umls:C0031391 | Phencyclidine Abuse | 1 | Biomarker |
| umls:C0033941 | Psychoses, Substance-Induced | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for CAMK2B |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Experimental | DB07168 | [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of CAMK2B go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 5CP | [4-({4-[(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO]-6-(METHYLAMINO)PYRIMIDIN-2-YL}AMINO)PHENYL]ACETONITRILE | 3bhh | B | V28 K43 V74 E140 | 5CP | [4-({4-[(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO]-6-(METHYLAMINO)PYRIMIDIN-2-YL}AMINO)PHENYL]ACETONITRILE | 3bhh | A | V28 V74 E140 |
| Top |
| Conservation information for LBS of CAMK2B |
| Multiple alignments for Q13554 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |